Navigation Links
Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
Date:6/12/2008

f May 21, 2008, 235 patients remained on belimumab treatment in the continuation study.

In June 2006, HGS reported the 52-week results of the Phase 2 trial, which demonstrated that belimumab significantly reduced disease activity versus placebo in patients with serologically active SLE across multiple clinical measures, exhibited clinically relevant biological activity, and appeared generally safe and well tolerated. Frequency and severity of adverse events were similar to placebo. Among the findings at Week 52 was a significantly improved response rate among serologically active patients, as defined by an improvement in SELENA SLEDAI score of 4 points or greater, no new BILAG A flare and no more than one new BILAG B flare, and no worsening in Physician's Global Assessment. This combination of measures is the primary efficacy endpoint in the ongoing pivotal Phase 3 clinical trials.

About LymphoStat-B (belimumab)

LymphoStat-B (belimumab) is a human monoclonal antibody that specifically recognizes and inhibits the biological activity of B-lymphocyte stimulator, or BLyS(R). BLyS is a naturally occurring protein discovered by HGS that is required for the development of B-lymphocyte cells into mature plasma B cells. Plasma B cells produce antibodies, the body's first line of defense against infection.

In lupus and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies - antibodies that attack and destroy the body's own healthy tissues. The presence of autoantibodies appears to correlate with disease severity. Pre-clinical and clinical studies demonstrate that B-cell antagonists can reduce autoantibody levels and help control autoimmune disease activity.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes nove
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
3. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
4. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
5. St. Jude Finds Dancing Hair Cells Are Key to Humans Acute Hearing
6. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
7. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
8. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
9. First Human Implant of New Archus Orthopedics Facet Replacement System
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 Regen BioPharma, Inc. (OTCBB: ... a novel means of delivering its patented (US ... liver tumors utilizing a clinically approved formulation as ... hurdles with gene silencing therapeutics in which the ... the whole body.  By utilizing a local delivery ...
(Date:8/31/2015)... 2015 BioLight Life ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, today announced that its cancer ... several new genetic markers with high potential to ... with bisphosphonate drugs and was able to repeat ...
(Date:8/31/2015)... 31, 2015  AMRI (NASDAQ: AMRI ) ... collaboration focused on the development, manufacture and marketing ... ("APIs"). The collaboration combines Saneca,s strength in extracting ... developing and manufacturing controlled substance APIs with AMRI,s ... processes into these facilities. The collaboration will also ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4
... April 28, 2011 There,s a sea change sweeping across the ... do they need to carry bottles of liquid and slow-acting pills ... a car, plane or when watching a 3-D movie. ... in the battle against motion-sickness, allowing people to easily avoid nausea ...
... (NYSE: CVS ) today announced it expects ... business of Universal American on Friday, April 29, 2011. ... shareholders cash consideration of $1.25 billion plus the excess ... Part D business, less Universal American,s outstanding trust preferred ...
Cached Medicine Technology:Zentrip Offers a 'Sea Change' in Stopping the Distress from Motion Sickness 2CVS Caremark to Complete Acquisition of Universal American's Medicare Part D Business 2CVS Caremark to Complete Acquisition of Universal American's Medicare Part D Business 3
(Date:8/31/2015)... ... 31, 2015 , ... CareSource, a nonprofit Ohio-based health plan, ... capacity, Michael will provide strategic leadership for CareSource’s marketing, branding, corporate communications and ... have contributed to the company’s rapid growth. As the CareSource business model expands ...
(Date:8/31/2015)... BAY PINES, FL (PRWEB) , ... August 31, 2015 , ... ... accessible, high quality healthcare to Veterans residing across southwest Florida by hiring more doctors ... added to the list of expanded services. , In early July, Dr. Anthony Jabre ...
(Date:8/31/2015)... ... September 01, 2015 , ... ... for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy ”. , ... Traumatic brain injury has been largely untreatable - with mostly palliative treatments only ...
(Date:8/31/2015)... ... , ... Since 1946, the doctors and staff at Clifton Dental Associates have ... arrives at the office, the staff will make them feel welcome and comfortable. ... create a complete dental treatment plan that is unique to each smile! NJ ...
(Date:8/31/2015)... ... August 31, 2015 , ... With the FCPX LUT Soft pack from Pixel Film Studios, editors ... Table that contains a mathematical formula for modifying an image. The LUT changes every pixel's ... CUBE LUT files. , FCPX LUT Soft requires Final Cut Pro X 10.2 or ...
Breaking Medicine News(10 mins):Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2
... 2011 The children most likely to walk or cycle ... and in an economically disadvantaged home, according to survey results ... Roman Pabayo of the University of Montreal Hospital Research Centre ... study is unique in that it follows the same group ...
... SATURDAY, July 2 (HealthDay News) -- Staying hydrated is critical ... have different hydration needs, so you need to assess your ... of Tennessee at Chattanooga. "Sweat rate is very simple ... as possible; exercise for half an hour and don,t drink ...
... News) -- Nausea and vomiting after waking from general anesthesia ... from 122 patients with severe postoperative nausea and vomiting (PONV) ... initially identified 41 genetic targets (single nucleotide polymorphisms -- SNPs) ... them to at least one SNP that was common to ...
... contain baked milk into the diets of children who have ... according to a study conducted at Mount Sinai School of ... the May 23 issue of the Journal of Allergy ... 2 to 17 years old, who were diagnosed with milk ...
... 1 (HealthDay News) -- Increasing daily soluble fiber intake may ... other substances linked to a host of chronic diseases, according ... found just under the skin, visceral fat is located deep ... Researchers at Wake Forest Baptist Medical Center found the way ...
... 1, 2011 Surgery and all its implications can be ... dread sometimes disfiguring scars. Now a UT Southwestern Medical ... that makes scarring virtually invisible yet is just as effective ... with minimally invasive surgery, leave the child with up to ...
Cached Medicine News:Health News:Urban children are healthier commuters than rural teens 2Health News:How to Stay Hydrated in Hot Weather 2Health News:Foods with baked milk may help build tolerance in children with dairy allergies 2Health News:Soluble Fiber Appears Key to Trimming 'Bad Fat' 2Health News:UT Southwestern pediatric urologist develops procedure to eliminate scarring in kidney surgeries 2
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTC/1Q chairs are recommended for ... clean room, static control, health care ...
... chairs with concave seats and ... • Select options like seats, ... glides. • BTT/1P chairs are ... industry, education, laboratory, clean room, ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With tubular ...
Medicine Products: